UTHR

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company founded in 1996 and headquartered in Silver Spring, Maryland. The company went public in 1999 and has evolved from a small biotech startup into a leading developer and commercializer of therapies for rare and life-threatening diseases. United Therapeutics specializes primarily in treatments for pulmonary arterial hypertension and related cardiovascular conditions, while also developing groundbreaking organ manufacturing technologies including xenotransplantation. The company has built a strong commercial foundation with multiple approved therapies generating nearly $3 billion in annual revenue, while simultaneously investing in revolutionary approaches to address organ shortage through bioengineered solutions.